Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XC7 in healthy volunteers
NCT04679493Phase 1Completed
- Start
- Dec 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of XC7 in coronavirus disease 2019 (COVID-19) (5 arms). Primary endpoint: Adverse Events. Started Dec 2020; status: completed.
02
Drugs
XC7
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04679493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04679493.